PMID- 26463246
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20191210
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
VI  - 11
IP  - 1
DP  - 2016
TI  - Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile.
PG  - 22-34
AB  - The increasing insights into the pathogenetic mechanisms of inflammatory 
      autoimmune arthritis and the development of innovative systems of industrial 
      production have led to discover molecules that are able to target/block other 
      molecules that play a critical role in the immune system functioning, and that 
      have been introduced in clinical practice alone and/or in addiction with other 
      "old" disease-modifying anti-rheumatic drugs. For this reason, such drugs are 
      currently known as "biological drugs" and include molecules that induce the 
      immunosuppression acting on several immune pathways. However, though the 
      biological drugs have been employed from more than a decade, there still exist 
      some drawbacks of their use, in particular about the high costs of this therapy 
      and their overall safety, including the route of administration for the 
      intravenous use. In this review we provide an update on the correct use and 
      current therapeutic indications of such drugs, including some of the new biologic 
      therapies that will be soon available for the clinical use, focusing on these 
      biological drugs: * Tumor necrosis factor-alpha (TNF-alpha) inhibitors 
      (adalimumab, certolizumab-pegol, etanercept, golimumab and infliximab); * The T 
      cell co-stimulation inhibitor, abatacept; * The anti-CD20 receptor monoclonal B 
      cell agent, rituximab; * The interlukin-6 (IL-6) receptor-blocking monoclonal 
      antibody, tocilizumab; * The interlukin-1 (IL-1) inhibitor, anakinra; * The 
      interlukin-IL17 (IL-17) pathway inhibitors (ustekinumab, secukinumab, 
      brodalumab).
FAU - Luchetti, Michele Maria
AU  - Luchetti MM
AD  - Dipartimento Scienze Cliniche e Molecolari, Sezione di Clinica Medica, Polo 
      Didattico, Universita Politecnica delle Marche, Via Tronto 10/A, 60020 Ancona, 
      Italy. m.luchetti@univpm.it.
FAU - Balloni, Andrea
AU  - Balloni A
FAU - Gabrielli, Armando
AU  - Gabrielli A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 6ZA31Y954Z (brodalumab)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy/immunology
MH  - Biological Therapy/adverse effects/*methods
MH  - Drug-Related Side Effects and Adverse Reactions/etiology/immunology
MH  - Humans
MH  - Inflammation Mediators/*antagonists & inhibitors/immunology
MH  - Infliximab/therapeutic use
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology
EDAT- 2015/10/16 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/10/15 06:00
PHST- 2015/07/15 00:00 [received]
PHST- 2015/09/27 00:00 [revised]
PHST- 2015/10/12 00:00 [accepted]
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - CDS-EPUB-71069 [pii]
AID - 10.2174/1574886310666151014115401 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2016;11(1):22-34. doi: 10.2174/1574886310666151014115401.